Aurora Cannabis: Upgrading On High-Margin Medical Cannabis Sales Growth - Buy (ACB)

Group 1 - The article highlights the strong performance of the analyst team, achieving an annualized return of almost 40% over the past decade with a long-only model portfolio return of over 23 times [1] - The focus is on providing income-focused picks for investors who prefer lower-risk firms with steady dividend payouts [1] Group 2 - The analyst has previously covered Aurora Cannabis Inc., indicating that this article serves as an update to earlier coverage [2] - The analyst has a historical focus on tech stocks but has expanded coverage to include the offshore drilling, supply industry, and shipping industry [3]